Taxoids (Taxanes)

03/01/2020 - "We performed a network meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of HER2-targeted agents in combination with taxanes and to identify the best strategy for HER2+ metastatic breast cancer (MBC). "
09/01/2006 - "The taxanes have been studied extensively and have been proven effective for treating early and advanced breast cancer. "
01/01/2012 - "However, GEICAM 9805 study has shown positive results on DFS in high-risk node-negative breast cancer patients with adjuvant taxanes."
01/01/2021 - "High FAS expression correlates with a better prognosis and efficacy of taxanes and target regents in breast cancer."
01/01/2007 - "Initially found to have efficacy in metastatic breast cancer, the taxanes are now vital components in the treatment of early-stage disease, in which their addition to adjuvant treatment of early breast cancer has been shown to improve overall survival. "

04/01/2013 - "Although taxanes are highly effective in cancer treatment, their use is associated with serious complications attributable to large interindividual variability in pharmacokinetics and a narrow therapeutic window. "
06/12/2008 - "Moreover, taxoid 19 exhibited excellent in vivo efficacy against highly drug-resistant CFPAC-1 pancreatic as well as DLD-1 human colon tumor xenografts in mice."
06/21/2016 - "Taxanes target microtubules and are clinically established chemotherapeutic agents with proven efficacy in human cancers. "
06/01/2013 - "Taxanes are important chemotherapeutic agents with proven efficacy in human cancers, but their use is limited by resistance development. "
01/01/2020 - "However, taxanes in first-line can be a treatment option for patients presenting with high tumor burden and strong pressure to achieve remission. "

10/01/2005 - "With 177Lu-J591, dose fractionation in combination with taxanes should be considered as an alternative approach to achieve optimal therapeutic efficacy in patients with prostate cancer."
01/01/2018 - "Since taxanes are widely used for the treatment of advanced prostate cancers, we present in this chapter protocols that allow the study of the prostate cancer sensitivity as well as determine the mechanisms of resistance to these chemotherapeutic agents."
01/01/2018 - "Protocols for the Study of Taxanes Chemosensitivity in Prostate Cancer."
03/01/2010 - "Other trials of ABCB1 genotyping in breast and prostate cancer patients receiving taxanes have shown inconsistent results. "
09/01/2007 - "Although there is a body of knowledge on the mechanisms of action of taxanes and resistance pathways, there are few clinical or translational studies in prostate cancer adequately assessing the modulation of these mechanisms. "

10/01/2014 - "Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer."
10/01/2012 - "Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer."
01/01/2003 - "Our objective of the present study was to examine the impact of prolonged exposure on the cytotoxicity of taxanes against non-small-cell lung carcinoma (NSCLC) cell lines and the clinical response and outcome of the patients. "
10/01/2014 - "Based on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-small-cell lung cancer (nsclc) and nsclc subtypes. "
05/01/2014 - "Taxanes, past, present, and future impact on non-small cell lung cancer."

01/01/2012 - "All studies that examined the efficacy and safety of taxanes administered during pregnancy in ovarian cancer, regardless of sample size, were considered eligible. "
01/01/2023 - "The lessons learned from both the successful development of the taxanes and camptothecins, as well as the strategies currently being employed for new drug development, are expected to ultimately help guide the future development of botanical natural products for ovarian cancer."
09/01/2022 - "Taxanes are a class of standard first-line chemotherapeutic agents for the treatment of ovarian cancer. "
12/22/2021 - "The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes."
11/30/2021 - "Despite the extensive use of taxanes in the treatment of ovarian cancer, little is known about expression of CHFR itself in this disease. "